KalVista says FDA delayed decision on HAE drug, citing ‘heavy workload’ 

KalVista Pharmaceuticals said Friday that the FDA pushed back its decision on whether to approve its on-demand oral drug for hereditary angioedema, citing “heavy workload and limited resources” at the agency. KalVista had expected the ...